G. Walmsley Graham, Director at Akero Therapeutics, Inc. (AKRO), bought 350,000 shares at $44.75 ($15.4M) on 2025-03-25, disclosed to the SEC on 2025-03-27.
Open-market purchase of $15.4M AKRO by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $44.75 | 91,309 | $4.1M | 26.5% |
| 2 | $44.75 | 91,309 | $4.1M | 26.5% |
| 3 | $43.01 | 58,691 | $2.5M | 16.4% |
| 4 | $43.01 | 58,691 | $2.5M | 16.4% |
| 5 | $43.55 | 50,000 | $2.2M | 14.1% |
| Total | $44.00 avg | 350,000 |
| $15.4M |
| 100% |
| Filing → |
| OLMA | SELL | 2024-12-18 | $9.5M | — | Filing → |
| OLMA | BUY | 2024-12-17 | $4.7M | — | Filing → |
| OLMA | SELL | 2024-12-17 | $9.5M | — | Filing → |